A Dark Horse Five Years In The Making: Legend Gains First Global Approval
First 'Made in China' Cell Therapy In US
Nanjing Legend gains FDA approval for its BCMA cell therapy, the second to go to market in the US marks a win for true innovators from China, not cheaper but similar products, some say.
You may also be interested in...
Johnson & Johnson reported disappointing Q1 sales for its COVID-19 vaccine but called the Carvykti launch solid and discussed plans for further diversification of its multiple myeloma portfolio.
Janssen priced the one-time autologous treatment at $465,000, well above the $419,500 list price for Bristol’s first-to-market CAR-T, but expects broad commercial and Medicare coverage.
China has fielded several homegrown checkpoint inhibitors, using lower cost as an argument for the US market, but sintilimab – a key test case – has underscored FDA skepticism.